登入
選單
返回
Google圖書搜尋
DNMT and HDAC Inhibition Induces Immunogenic Neoantigens from Human Endogenous Retroviral Element-derived Transcripts
Ashish Goyal
Jens Bauer
Joschka Hey
Dimitris N. Papageorgiou
Ekaterina Stepanova
Michael Daskalakis
Jonas Scheid
Marissa Dubbelaar
Boris Klimovich
Dominic Schwarz
Melanie Märklin
Malte Roerden
Tobias Ma
Oliver Mücke
Hans-Georg Rammensee
Michael Lübbert
Fabricio Loayza-Puch
Jeroen Krijgsveld
Juliane S. Walz
Christoph Plass
出版
Universität
, 2023
URL
http://books.google.com.hk/books?id=vKdr0AEACAAJ&hl=&source=gbs_api
註釋
Abstract: Immunotherapies targeting cancer-specific neoantigens have revolutionized the treatment of cancer patients. Recent evidence suggests that epigenetic therapies synergize with immunotherapies, mediated by the de-repression of endogenous retroviral element (ERV)-encoded promoters, and the initiation of transcription. Here, we use deep RNA sequencing from cancer cell lines treated with DNA methyltransferase inhibitor (DNMTi) and/or Histone deacetylase inhibitor (HDACi), to assemble a de novo transcriptome and identify several thousand ERV-derived, treatment-induced novel polyadenylated transcripts (TINPATs). Using immunopeptidomics, we demonstrate the human leukocyte antigen (HLA) presentation of 45 spectra-validated treatment-induced neopeptides (t-neopeptides) arising from TINPATs. We illustrate the potential of the identified t-neopeptides to elicit a T-cell response to effectively target cancer cells. We further verify the presence of t-neopeptides in AML patient samples after in vivo treatment with the DNMT inhibitor Decitabine. Our findings highlight the potential of ERV-derived neoantigens in epigenetic and immune therapies